Dyno Therapeutics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 35)
Dyno Therapeutics logo

Dyno Therapeutics

EmergingLife Sciences & BioTech

AI-Powered AAV Capsid Engineering for Gene Therapy

Dyno Therapeutics uses AI and high-throughput synthesis to engineer next-generation AAV gene therapy vectors with improved tissue targeting, manufacturability, and immune evasion; raised $100M Series B;

AI VisibilityBeta
Overall Score
D35
Category Rank
#158 of 198
AI Consensus
70%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
37
Gemini
30

About

Dyno Therapeutics is a Cambridge, Massachusetts-based gene therapy biotechnology company founded in 2018 by George Church (Harvard), Eric Kelsic, and Sam Sinai. The company's core insight is that the adeno-associated virus (AAV) — the dominant vector for approved gene therapies — has enormous untapped diversity in its capsid protein sequences, and that AI can be used to explore this diversity space far more efficiently than directed evolution or rational design alone. Dyno's platform generates hundreds of thousands of synthetic AAV capsid variants, characterizes their properties in high-throughput cell and animal assays, and uses machine learning to learn the sequence-function relationships that determine tissue targeting, manufacturing yield, and immune evasion.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

35
Overall Score
74
#158
Category Rank
#11
70
AI Consensus
68
stable
Trend
stable
39
ChatGPT
71
37
Perplexity
68
30
Gemini
80
29
Claude
77
39
Grok
69

Key Details

Category
AI-Powered AAV Capsid Engineering for Gene Therapy
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.